Tuberculosis control policies in major metropolitan health departments in the United States: VI. Standard of practice in 1996

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 5, 1997, Pages 1487-1494

  Leff, Donna R ^b   Leff, Alan R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; BUDGET; CHILD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0030656225     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.5.9704105     Document Type: Article

References (25)

1. Leff, A. R., D. Herskowitz, J. Gibert, and A. Brewin. 1979. Tuberculosis chemoprophylaxis practices in metropolitan clinics. Am. Rev. Respir. Dis. 119-164.
2. Leff, D. R., A. R. Leff, and A. Brewin. 1981. Tuberculosis chemotherapy practices in major metropolitan health departments in the United States. Am. Rev. Respir. Dis. 144:745-749.
3. Leff, D. R., and A. R. Leff. 1985. Tuberculosis control practices in major metropolitan health departments in the Untied States. 3. Standard of practice in 1984. Chest 87:206-211.
4. Leff, D. R., and A. R. Leff. 1989. Tuberculosis control policies in major metropolitan health departments in the United States. IV. Standards in 1988. Am. Rev. Respir. Dis. 139:1350-1355.
5. Leff, D. R., and A. R. Leff. 1993. Tuberculosis control policies in major metropolitan health departments in the United States. V. Standards in 1992. Am. Rev. Respir. Dis. 148:1530-1536.
6. Small, P. M., G. F. Schechter, P. C. Goodman, M. A. Sande, R. E. Chaisson, and P. C. Hopewell. 1991. Treatment of tuberculosis in patients with advanced human immunodeficiency infection. N. Engl. J. Med. 324:289-294.
7. Brudney, K., and J. Dobkin. 1991. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am. Rev. Respir. Dis. 144:745-749.
8. Daley, C. L., P. M. Small, G. F. Schlechter, G. K. Schoolnick, R. A. McAdam, W. R. Jacobs, and P. C. Hopewell. 1992. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. Am. Rev. Respir. Dis. 326:231-235.
9. Horsburgh, C. R., Jr., and R. M. Selik. 1989. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am. Rev. Respir. Dis. 139:4-7.
10. Chaisson, R. W., R. D. Moore, D. D. Richman, J. Keruly, T. Creagh, and the Zidovudine Epidemiology Study Group. 1992. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am. Rev. Respir. Dis. 146:285-289.
11. Chaisson, R. E., and P. C. Hopewell. 1989. Mycobacteria and AIDS mortality. Am. Rev. Respir. Dis. 139:1-3.
12. Department of Health and Human Services. USPHS. Centers for Disease Control. 1996. TB Notes 4:1-2.
13. Peter, G., editor. 1994. Tuberculosis. 1994 Red Book: Report on the Committee on Infectious Diseases. American Academy of Pediatrics. 480-500.
14. Jordan, T. J., and L. B. Reichman. 1991. Isoniazid preventive therapy for tuberculosis: decision analysis considering ethnicity and gender. Am. Rev. Respir. Dis. 144:1357-1360.
15. Specter, M. Panel proposes stronger steps to curb TB. The New York Times. November 30, 1992. A1 and B12.
16. Villarino, M. E., R. Ridzon, R. C. Weismuller, M. Elcock, R. M. Maxwell, J. Meador, P. J. Smith, M. L. Carson, and L. J. Geiter. 1997. Rifampin preventive therapy for tuberculosis infection. Am. J. Respir. Crit. Care Med. 155:1735-1738.
17. Nolan, C. M., A. M. Elarth, H. Barr, A. M. Saeed, and D. R. Risser. 1991. An outbreak of tuberculosis in a shelter for homeless men. Am. Rev. Respir. Dis. 143:257-261.
18. El-Solh, A. J., J. Mylotte, S. Sherif, J. Serghani, and B. J. B. Grant. 1997. Validity of a decision tree for predicting active tuberculosis. Am. J. Respir. Crit. Care Med. 155:1711-1716.
19. Iseman, M. D., and J. A. Sbarbaro. 1991. Short-course chemotherapy of tuberculosis. Am. Rev. Respir. Dis. 143:697-698.
20. Combs, D. L., R. J. O'Brien, and L. J. Geiter. 1990. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, acceptability. Ann. Intern. Med. 112:397-406.
21. Cohn, D. L., B. J. Catlin, K. L. Peterson, F. N. Judson, and J. A. Sbarbaro. 1990. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. Ann. Intern. Med. 112:407-415.
22. Barnes, P. F., A. B. Bloch, P. T. Davidson, and D. E. Snider, Jr. 1991. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 324:1644-1650.
23. Perriens, J. H., R. L. Colebunders, C. Karahunga, J.-C. Willame, J. Jeugmans, M. Kaboto, Y. Mukadi, P. Pauwels, R. W. Rynder, J. Prignot, and P. Piot. 1991. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am. Rev. Respir. Dis. 144:750-755.
24. Altman, L. K. Top scientist warns tuberculosis could become major threat. The New York Times, February 11, 1992, 6.
25. The tuberculosis failure (editorial). The New York Times, April 26, 1992, Section A:18.